SCHEMBL4132949

SCHEMBL4132949

Cc1ccc(S(=O)(=O)c2cc(C)c(O)c(C(=O)O)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHLPP2 Q6ZVD8 1/20 0.52
GAA P10253 2/20 0.50
HMGB1 P09429 1/20 0.46
CXCL12 P48061 1/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
BCL2L1 Q07817 1/20 0.45
RAPGEF4 Q8WZA2 1/20 0.45
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CSNK2A1 P68400 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4120980 0.88 BCL2L1 (0.59) PHLPP2HMGB1CXCL12ALDH1A1MAPT
SCHEMBL4129021 0.88 PHLPP2 (0.50) PHLPP2HMGB1CXCL12ALDH1A1MAPT
SCHEMBL4869370 0.88 GAA (0.50) PHLPP2GAAALDH1A1KMT2AAKR1C2
SCHEMBL4128140 0.84 KMT2A (0.48) PHLPP2HMGB1CXCL12ALDH1A1MAPT
SCHEMBL15745644 0.82 GAA (0.55) GAAALDH1A1MAPTHTTRAPGEF4
SCHEMBL8962291 0.80 APEX1 (0.60) GAAALDH1A1MAPTMEN1HTT
SCHEMBL11343478 0.78 PHLPP2 (0.63) PHLPP2GAAHMGB1CXCL12ALDH1A1
SCHEMBL10935405 0.77 HMGB1 (0.51) PHLPP2HMGB1CXCL12ALDH1A1MEN1
SCHEMBL7514015 0.76 MCL1 (0.52) GAAALDH1A1KMT2ALMNAPKM
SCHEMBL18833185 0.75 GAA (0.59) GAAALDH1A1MAPTMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192190-A1 Benzoic Acid Derivatives that are Modulators or Agonists of GlyR ASTRAZENECA AB (SE) 2009-07-30 US claimed
EP-1890993-A2 BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR AstraZeneca AB (SE) 2008-02-27 EP claimed
WO-2006121390-A2 BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR ASTRAZENECA AB (SE) 2006-11-16 WO claimed
US-20090192190-A1 Benzoic Acid Derivatives that are Modulators or Agonists of GlyR ASTRAZENECA AB (SE) 2009-07-30 US disclosed
EP-1890993-A2 BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR AstraZeneca AB (SE) 2008-02-27 EP disclosed
WO-2006121390-A2 BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR ASTRAZENECA AB (SE) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192190-A1 Benzoic Acid Derivatives that are Modulators or Agonists of GlyR GLRA1, GLRB, GPBAR1 PHLPP2 2402/4885GAA 831/4885HMGB1 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.